TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment Options for Metastatic or Recurrent GISTs
Source: Gastrointestinal Stromal Tumors Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: December 13, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Metastatic or Recurrent GISTs
Treatment options for metastatic or recurrent gastrointestinal stromal tumors (GISTs) include:
Initial tyrosine kinase inhibitor (TKI) therapy.
Source links and citations
Initial TKI therapy for PDGFRA D842-variant GISTs.
Source links and citations
TKI therapy for imatinib-resistant GISTs.
Source links and citations
Additional TKI therapy options.
Source links and citations
TKI therapy for KIT/PDGFRA wild-type GISTs.
Source links and citations
Surgery.
Source links and citations
Clinical trials.
Source links and citations
The primary treatment of patients with metastatic or recurrent GISTs involves medical therapy with a TKI. In select cases, surgical therapy may be added. Patients with metastatic or recurrent tumors that do not respond to these measures may be candidates for clinical trials.
Continue within this section
Preserved source evidence · Not medical advice